Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
From ‘Project Hail Mary’ to Artemis II, spaceflight captures audiences when it centers on people because human space travel is hazardous - 2Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- 3Upgrading the Healthy benefit of Your Local Vegetables
- 4Sophie Kinsella, 'Confessions of a Shopaholic' author, dies at 55 after battle with cancer
- 5Israel and Iran continue tit-for-tat attacks
- Zendaya serves bridal-coded fashion with old, new and borrowed gowns for ‘The Drama’ press tour
- Manual for Instructive Application for Youngsters
- How one man's concern saved his brothers from heart disease
- 4 DSLR Cameras for Amateurs in 2024
- Vote in favor of your favored spot to peruse
- Top German court to rule on claims by Wirecard shareholders
- 'Outrageous and illegal' : UNRWA slams Israel for cutting off its water, comms and electric in Gaza
- Mummified cheetahs found in Saudi caves shed light on lost populations
- How did life begin on Earth? New experiments support 'RNA world' hypothesis
